A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
Launched by HOFFMANN-LA ROCHE · Jan 25, 2010
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, \>/=18 years of age
- • chronic lymphocytic leukemia
- • active CLL with progressive Binet stage B or C
- • ineligible for treatment with fludarabine
- • for second line patients, only pretreatment with rituximab and/or chlorambucil is allowed
- • EOCG performance status \>/=2
- Exclusion Criteria:
- • patients who have relapsed within \<12 months of first dose of prior rituximab or chlorambucil first-line therapy
- • previous or planned stem cell transplantation
- • radioimmunotherapy within 6 months prior to starting study treatment
- • transformation to aggressive B-cell malignancy
- • any other concurrent anti-cancer therapy, or glucocorticoid \>/=20mg daily prednisolone or equivalent
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto, , Portugal
Edinburgh, , United Kingdom
Manchester, , United Kingdom
Izmir, , Turkey
Barcelona, , Spain
Valencia, , Spain
London, , United Kingdom
Elche, Alicante, Spain
Pierre Benite, , France
Zaragoza, , Spain
Malaga, , Spain
Oxford, , United Kingdom
Brest, , France
Nice, , France
Nimes, , France
Paris, , France
Uppsala, , Sweden
Maidstone, , United Kingdom
Bordeaux, , France
Limoges, , France
La Tronche, , France
Perpignan, , France
Salouel, , France
Leeds, , United Kingdom
Coimbra, , Portugal
Ankara, , Turkey
Lyon, , France
Avignon, , France
Salamanca, , Spain
Vantaa, , Finland
Sevilla, , Spain
Istanbul, , Turkey
Madrid, , Spain
Sundsvall, , Sweden
Bournemouth, , United Kingdom
Truro, , United Kingdom
Alcorcon, Madrid, Spain
Marseille, , France
Leon, , Spain
Murcia, , Spain
Le Mans, , France
Argenteuil, , France
Pori, , Finland
Jerez De La Frontera, Cadiz, Spain
La Coruna, La Coruña, Spain
Huelva, , Spain
Mulhouse, , France
Kristianstad, , Sweden
Bursa, , Turkey
Kayseri, , Turkey
Samsun, , Turkey
Falun, , Sweden
La Roche Sur Yon, , France
Tarragona, , Spain
Blackpool, , United Kingdom
Romford, , United Kingdom
Kocaeli, , Turkey
Vitoria, Alava, Spain
Torrelavega, Cantabria, Spain
Blois, , France
Lens, , France
Lisboa, , Portugal
Cartagena, Murcia, Spain
Luleå, , Sweden
Uddevalla, , Sweden
Umea, , Sweden
Tunis, , Tunisia
Edirne, , Turkey
Somerset, , United Kingdom
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials